The results showed that 11,000 women would have to be screened to prevent one case of SMA, at a cost of 4.7 million dollars per case averted.
"Our findings show that screening everyone for SMA is not cost effective," said one of the study's authors, Dr. Sarah Little of Massachusetts General Hospital. "Our results, however, were most sensitive to changes in the baseline prevalence of disease, suggesting that prenatal SMA screening may be cost effective in high risk populations, such as those with a family history of disease."
Source-Eurekalert
RAS